Evidence map›Paper›PMID 18292805›Full record

ArticleThe Journal of clinical investigation2008

Discovering early molecular determinants of leukemogenesis.

Grover C Bagby

Open access · bronzeAbstract readComment
In one paragraph

Article in The Journal of clinical investigation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Herbal management of hepatocellular carcinoma through cutting the pathways of the common risk factors.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2018
    Review
  3. In Vitro Screening for Cytotoxic Activity of Herbal Extracts.Evidence-based complementary and alternative medicine : eCAM · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Grover C BagbyDepartment of Medicine and Molecular and Medical Genetics, Oregon Health and Sciences University, Oregon, USA. grover@ohsu.edu
Oregon Health & Science University · US

Funding

Xenograft CoreP01HL048546 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI FLEMING, WILLIAM H · 1994 to 2020
$36.4M
Microarray Program for NHLBI InvestigatorsR01HL072321 · NHLBI · OREGON HEALTH AND SCIENCE UNIVERSITY · PI BAGBY, GROVER CARLTON · 2002 to 2005
$2.9M
NHLBI NIH HHS P01 HL048546NHLBI NIH HHS R01 HL072321
6 · The paper itself

Abstract

Truncating mutations of the G-CSF receptor are found during disease course in nearly half of all patients with severe congenital neutropenia. In this issue of the JCI, Liu et al. demonstrate that these mutations confer a competitive clonal advantage upon HSCs in mice and that the advantage is conditional because it is observed only in the presence of the ligand G-CSF (see the related article beginning on page 946). Once activated, the mutant receptor requires the function of Stat5 in order to effect clonal expansion of this stem cell population. The results support the notion that early molecular steps in this and other neoplastic processes represent adaptations in which, through somatic mutations, "unfit" stem cells gain a measure of fitness by altering their relationships with their microenvironment.

Indexed as

MutationAnimalsFanconi AnemiaGranulocyte Colony-Stimulating FactorHematopoietic Stem CellsLeukemiaMiceNeutropeniaReceptors, Granulocyte Colony-Stimulating FactorSTAT5 Transcription FactorGranulocyte Colony-Stimulating FactorReceptors, Granulocyte Colony-Stimulating FactorSTAT5 Transcription Factor

Identifiers

PMID18292805
PMCPMC2248429
OpenAlexW2017189164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.